介质素-37有助于子宫内膜再生细胞介导的免疫治疗作用,对慢性异体移植血管病变产生影响
Yafei Qin1, Bo Shao2, Shao-Hua Ren2
1Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, PR China; Department of Vascular Surgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, PR China.
Cytotherapy
|December 30, 2023
概括
介质素-37 (IL-37) 对子宫内膜再生细胞 (ERC) 是必不可少的,以预防移植后的慢性异位血管病变 (CAV). 这项研究表明,IL-37调解了ERCs的免疫调节作用,改善了长期的全移植接受度.
科学领域:
- 免疫学 免疫学 免疫学
- 再生医学是一种再生医学.
- 移植生物学 移植生物学
背景情况:
- 慢性异位移植血管病变 (CAV) 是移植后晚期异位移植失败的主要原因.
- 迫切需要有效的疗法来抑制CAV的进展.
- 子宫内膜再生细胞 (ERC) 显示出治疗潜力,但它们的免疫调节机制需要阐明.
研究的目的:
- 调查介素-37 (IL-37) 在治疗CAV的ERCs免疫调节功能中的作用.
- 确定IL-37是否对于ERC介导的CAV预防是不可或缺的.
主要方法:
- 小鼠腹腔大动脉移植模型 (C57BL/6接受者,BALB/c捐赠者).
- 治疗组:ERCs,负控制 (NC) -ERCs和IL-37淘汰赛 (KO) -ERCs.
- 分析包括移植病理,免疫细胞种群,捐赠者特异性抗体和细胞因子概况.
主要成果:
- IL-37分泌的ERC显著降低了CAV病理,包括血管狭窄和内脏增生.
- ERCs调节T细胞反应,增加调节性T细胞 (Tregs) 和减少Th1/Th17细胞.
- IL-37分泌的ERC抑制了促炎性细胞因子和供体特异性抗体的产生.
结论:
- IL-37对于ERC在预防CAV的治疗效果是不可或缺的.
- IL-37调解ERCs的免疫调节效应,增强长期全移植接受度.
相关概念视频
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529


